Clinical readout
AusperBio's AHB-137 keeps hepatitis B functional cure 15 months off therapy
In long-term follow-up of phase 2 responders, every participant reaching the 15-month mark after stopping all hepatitis B treatment remained functionally cured, nine pretreated and six treatment-naive. No clinical relapse or new safety signal was seen. The antisense drug is in phase 3 in China.
- DrugAHB-137
- CompanyAusperBio
- TargetHepatitis B virus messenger RNAs at three well-conserved genomic regions across multiple HBV genotypes
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.